Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators.

N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.

PMID:
31851799
2.

Long-term phytomanagement with compost and a sunflower - Tobacco rotation influences the structural microbial diversity of a Cu-contaminated soil.

Burges A, Fievet V, Oustriere N, Epelde L, Garbisu C, Becerril JM, Mench M.

Sci Total Environ. 2020 Jan 15;700:134529. doi: 10.1016/j.scitotenv.2019.134529. Epub 2019 Oct 8.

PMID:
31693956
3.

Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F.

Cancer Manag Res. 2019 Aug 14;11:7673-7684. doi: 10.2147/CMAR.S210004. eCollection 2019.

4.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
5.

EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.

Czogalla B, Kuhn C, Heublein S, Schmöckel E, Mayr D, Kolben T, Trillsch F, Burges A, Mahner S, Jeschke U, Hester A.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4.

PMID:
31485769
6.

Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.

Dötzer K, Schlüter F, Schoenberg MB, Bazhin AV, von Koch FE, Schnelzer A, Anthuber S, Grab D, Czogalla B, Burges A, Werner J, Mahner S, Mayer B.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1250. doi: 10.3390/cancers11091250.

7.

Inhibitor of apoptosis proteins are potential targets for treatment of granulosa cell tumors - implications from studies in KGN.

Bagnjuk K, Kast VJ, Tiefenbacher A, Kaseder M, Yanase T, Burges A, Kunz L, Mayr D, Mayerhofer A.

J Ovarian Res. 2019 Aug 14;12(1):76. doi: 10.1186/s13048-019-0549-6.

8.

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.

Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

Int J Cancer. 2020 Jan 15;146(2):439-448. doi: 10.1002/ijc.32606. Epub 2019 Sep 6.

PMID:
31381147
9.

Extracapsular Lymph Node Involvement in Ovarian Carcinoma.

Heublein S, Schulz H, Marmé F, Angele M, Czogalla B, Burges A, Mahner S, Mayr D, Jeschke U, Schmoeckel E.

Cancers (Basel). 2019 Jul 1;11(7). pii: E924. doi: 10.3390/cancers11070924.

10.

Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients.

Deuster E, Mayr D, Hester A, Kolben T, Zeder-Göß C, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B.

Int J Mol Sci. 2019 Jun 12;20(12). pii: E2862. doi: 10.3390/ijms20122862.

11.

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).

Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.

J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.

PMID:
30979843
12.

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B.

Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1.

PMID:
30936122
13.

Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.

Winterhoff B, Kommoss S, Heitz F, Konecny GE, Dowdy SC, Mullany SA, Park-Simon TW, Baumann K, Hilpert F, Brucker S, du Bois A, Schröder W, Burges A, Shen S, Wang J, Tourani R, Ma S, Pfisterer J, Aliferis CF.

AMIA Annu Symp Proc. 2018 Dec 5;2018:1093-1102. eCollection 2018.

14.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
15.

Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.

Schmoeckel E, Hofmann S, Fromberger D, Rottmann M, Luthardt B, Burges A, Jeschke U, Kirchner T, Lax SF, Mayr D.

Virchows Arch. 2019 May;474(5):599-608. doi: 10.1007/s00428-019-02528-6. Epub 2019 Feb 7.

PMID:
30734108
16.

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients.

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F.

Int J Mol Sci. 2018 Dec 29;20(1). pii: E112. doi: 10.3390/ijms20010112.

17.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
18.

Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results.

Walter F, Maihöfer C, Schüttrumpf L, Well J, Burges A, Ertl-Wagner B, Mahner S, Belka C, Gallwas J, Corradini S.

Brachytherapy. 2018 Sep - Oct;17(5):775-781. doi: 10.1016/j.brachy.2018.05.009. Epub 2018 Jun 22.

19.

Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening.

Hertlein L, Zeder-Göß C, Fürst S, Bayer D, Trillsch F, Czogalla B, Mahner S, Burges A, Rittler P.

Arch Gynecol Obstet. 2018 Jun;297(6):1533-1538. doi: 10.1007/s00404-018-4759-8. Epub 2018 Apr 5.

PMID:
29623417
20.

Cyclic transcutaneous bleeding after repeated cesarean section deliveries.

Czogalla B, Trillsch F, Burges A.

Am J Obstet Gynecol. 2018 Aug;219(2):202. doi: 10.1016/j.ajog.2018.03.006. Epub 2018 Mar 13. No abstract available.

PMID:
29548753
21.

No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas.

Trillsch F, Eichhorn P, Oliveira-Ferrer L, Kuempfel T, Burges A, Mahner S, Havla J.

J Neurol. 2018 Feb;265(2):431-432. doi: 10.1007/s00415-017-8717-3. Epub 2017 Dec 22. No abstract available.

PMID:
29273845
22.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

23.

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U.

Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18.

24.

From phytoremediation of soil contaminants to phytomanagement of ecosystem services in metal contaminated sites.

Burges A, Alkorta I, Epelde L, Garbisu C.

Int J Phytoremediation. 2018 Mar 21;20(4):384-397. doi: 10.1080/15226514.2017.1365340. Review.

PMID:
28862473
25.

The impact of phosphate-balanced crystalloid infusion on acid-base homeostasis (PALANCE study): study protocol for a randomized controlled trial.

Pagel JI, Hulde N, Kammerer T, Schwarz M, Chappell D, Burges A, Hofmann-Kiefer K, Rehm M.

Trials. 2017 Jul 10;18(1):313. doi: 10.1186/s13063-017-2051-z.

26.

Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes.

Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, Schubert-Fritschle G, Engel J.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1833-1844. doi: 10.1007/s00432-017-2422-6. Epub 2017 Apr 26.

PMID:
28447160
27.

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J.

Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3.

28.

Ecosystem services and plant physiological status during endophyte-assisted phytoremediation of metal contaminated soil.

Burges A, Epelde L, Blanco F, Becerril JM, Garbisu C.

Sci Total Environ. 2017 Apr 15;584-585:329-338. doi: 10.1016/j.scitotenv.2016.12.146. Epub 2016 Dec 29.

PMID:
28040210
29.

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).

Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück HJ, Meier W, Fehm T, du Bois A.

Int J Gynecol Cancer. 2016 Nov;26(9):1636-1641.

PMID:
27654266
30.

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S.

Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27468640
31.

Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.

Muallem MZ, Dimitrova D, Pietzner K, Richter R, Feldheiser A, Scharfe I, Schmeil I, Hösl TM, Mustea A, Wimberger P, Burges A, Kimmig R, Sehouli J.

Anticancer Res. 2016 Aug;36(8):4227-32.

PMID:
27466536
32.

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2016 Aug;27(8):1505-10. doi: 10.1093/annonc/mdw238. Epub 2016 Jul 11.

PMID:
27407100
33.

Neoadjuvant chemotherapy in ovarian cancer revisited.

Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, Burges A, Weissenbacher T, du Bois A.

Ann Oncol. 2016 Apr;27 Suppl 1:i30-i32. doi: 10.1093/annonc/mdw092.

PMID:
27141067
34.

Enhancement of ecosystem services during endophyte-assisted aided phytostabilization of metal contaminated mine soil.

Burges A, Epelde L, Benito G, Artetxe U, Becerril JM, Garbisu C.

Sci Total Environ. 2016 Aug 15;562:480-492. doi: 10.1016/j.scitotenv.2016.04.080. Epub 2016 Apr 22.

PMID:
27107647
35.

Trends in surgery and outcomes of squamous cell vulvar cancer patients over a 16-year period (1998-2013): a population-based analysis.

Rottmann M, Beck T, Burges A, Dannecker C, Kiechle M, Mayr D, Schlesinger-Raab A, Schubert-Fritschle G, Engel J.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1331-41. doi: 10.1007/s00432-016-2135-2. Epub 2016 Mar 14.

PMID:
26973058
36.

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.

Br J Clin Pharmacol. 2015 Nov;80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22.

37.

Laparoscopic reconstruction of an iatrogenic perforation of the neovagina and urinary bladder by a neovaginal dilator in a patient with Mayer-Rokitansky-Küster-Hauser syndrome.

Khoder WY, Stief CG, Burgmann M, Burges A.

Int Urogynecol J. 2015 Jul;26(7):1083-7. doi: 10.1007/s00192-014-2609-1. Epub 2015 Jan 15.

PMID:
25588908
38.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.

Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A.

Br J Cancer. 2015 Feb 17;112(4):660-6. doi: 10.1038/bjc.2014.648. Epub 2015 Jan 6.

39.

Impact of repeated single-metal and multi-metal pollution events on soil quality.

Burges A, Epelde L, Garbisu C.

Chemosphere. 2015 Feb;120:8-15.

PMID:
25462295
40.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C.

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):874-889. No abstract available.

41.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A.

Ann Oncol. 2014 Jul;25(7):1320-7. doi: 10.1093/annonc/mdu119. Epub 2014 Mar 11.

42.

Quality of life as a primary endpoint in ovarian cancer trials.

Mahner S, Burges A.

Lancet Oncol. 2014 Apr;15(4):363-4. doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28. No abstract available.

PMID:
24582485
43.

Malnutrition and clinical outcome in gynecologic patients.

Hertlein L, Kirschenhofer A, Fürst S, Beer D, Göß C, Lenhard M, Friese K, Burges A, Rittler P.

Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:137-40. doi: 10.1016/j.ejogrb.2013.12.028. Epub 2014 Jan 14.

PMID:
24485666
44.

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Heublein S, Grasse K, Hessel H, Burges A, Lenhard M, Engel J, Kirchner T, Jeschke U, Mayr D.

BMC Cancer. 2013 Oct 18;13:483. doi: 10.1186/1471-2407-13-483.

45.

Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.

Eur J Cancer. 2013 May;49(8):1905-14. doi: 10.1016/j.ejca.2013.01.035. Epub 2013 Mar 13.

PMID:
23490647
46.

[Uterine leiomyomas: how to proceed].

Fürst S, Lenhard M, Burges A, Friese K.

MMW Fortschr Med. 2012 Nov 15;154(20):61-3. German. No abstract available.

PMID:
23234123
47.

Human epididymis protein 4 (HE4) in benign and malignant diseases.

Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, Burges A.

Clin Chem Lab Med. 2012 Dec;50(12):2181-8.

PMID:
23093276
48.

[Unexplained pelvic pain: is it endometriosis?].

Hertlein L, Lenhard M, Burges A, Friese K.

MMW Fortschr Med. 2012 Aug 23;154(14):64-7; quiz 68-9. Review. German. No abstract available.

PMID:
22957460
49.

Circulating microparticles in patients with benign and malignant ovarian tumors.

Rank A, Liebhardt S, Zwirner J, Burges A, Nieuwland R, Toth B.

Anticancer Res. 2012 May;32(5):2009-14.

PMID:
22593480
50.

The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humans.

Jacob M, Chappell D, Hofmann-Kiefer K, Helfen T, Schuelke A, Jacob B, Burges A, Conzen P, Rehm M.

Crit Care. 2012 May 16;16(3):R86. doi: 10.1186/cc11344.

Supplemental Content

Loading ...
Support Center